MacroGenics has dosed the first patient in a Phase 1 clinical trial for MGC030, a novel antibody-drug conjugate targeting advanced solid tumors. This early-stage study aims to evaluate the safety, tolerability, and preliminary effectiveness of MGC030 in patients with various hard-to-treat cancers, including urothelial, colorectal, and pancreatic cancers. The trial will also explore biomarkers to better understand the drug's impact. This milestone marks MacroGenics' third antibody-drug conjugate in clinical development, highlighting its commitment to innovative cancer therapies.
MacroGenics' Phase 1 study dosing news is presented with Pluang's health sector market data for context. As of Oct 16, 2026 02:03 WIB, 126 of 150 health-sector US stocks on Pluang rose while 21 fell. Notable movers include ABEO at USD 4.67 with a 7.11% increase, MRVI at USD 6.96 up 6.34%, and MRNA at USD 239.40 rising 5.79%.
HDFC Bank is set to announce its quarterly earnings on October 17, 2026, with analysts expecting $0.40 earnings per share and $4.92 billion in revenue. The bank's valuation shows a trailing earnings multiple of 14.45x and a debt-to-equity ratio of 0....
Kohl's Chief Legal and Corporate Affairs Officer Jennifer J. Kent sold 18,352 shares for $403,744 on October 15, 2026, reducing her stake to 211,512 shares. Market opinions on Kohl's stock are divided, with some analysts expecting a decline while oth...
ManpowerGroup reported Q3 2026 revenue of $4.84 billion, slightly below estimates, with adjusted earnings per share at $1.01 matching expectations. Revenue grew 4% year-over-year, driven by strong U.S. Manpower and improving Experis segments. The com...
Copper exploration in British Columbia is increasingly relying on induced polarization (IP) geophysical surveys, which measure electrical chargeability and resistivity in rocks to identify sulphide mineralization associated with copper deposits. Gold...
The S&P 500 index has increased by 30.6% during the first 20 months of Donald Trump's second presidential term, slightly surpassing the 28.5% gain recorded in the same period of his first term. This comparison is significant for investors as it provi...
